Literature DB >> 31023428

Lifestyle, Glycosylated Hemoglobin A1c, and Survival Among Patients With Stable Ischemic Heart Disease and Diabetes.

G B John Mancini1, David J Maron2, Pamela M Hartigan3, John A Spertus4, William J Kostuk5, Daniel S Berman6, Koon K Teo7, William S Weintraub8, William E Boden9.   

Abstract

BACKGROUND: The importance of glycosylated hemoglobin A1c (A1c) control as part of comprehensive risk factor management in patients with stable ischemic heart disease (SIHD) and diabetes mellitus (DM) is controversial.
OBJECTIVES: The purpose of this study was to determine whether a greater number of controlled risk factors at 1 year, including A1c, affects survival in patients with DM and SIHD.
METHODS: Of 690 patients with DM followed in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial, 592 (86%) had complete ascertainment of 7 pre-specified risk factors at baseline and after 1 year: systolic blood pressure, low-density lipoprotein cholesterol, nonsmoking, physical activity, diet adherence, body mass index, and A1c. The primary outcome measure was mortality beyond 1 year after randomization.
RESULTS: During a mean follow-up of 7.0 ± 4.2 years beyond 1 year after randomization, 186 subjects died (31.4% overall, 4.5%/year). The greater the number of risk factors controlled at 1 year, the higher the probability of survival (unadjusted log rank p = 0.002). Compared with 0 to 1 controlled risk factors, attaining 3 to 7 goals predicted progressively lower mortality (hazard ratio for control of 6 or 7 risk factors was 0.13; 95% confidence interval: 0.05 to 0.40). Importantly, only 10.3% of subjects achieved control of 6 or 7 risk factors. In multivariate analysis, the strongest predictors of improved survival were no smoking, regular physical activity, dietary adherence, and A1c <7%.
CONCLUSIONS: In this high-risk subset of SIHD patients with DM, the number of controlled risk factors, particularly lifestyle behaviors and A1c, were associated with improved survival. (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation; NCT00007657).
Copyright © 2019 American College of Cardiology Foundation. All rights reserved.

Entities:  

Keywords:  diabetes; guideline-directed medical therapy; hemoglobin A1c; lifestyle; optimal medical therapy; secondary prevention; stable ischemic heart disease

Year:  2019        PMID: 31023428     DOI: 10.1016/j.jacc.2018.11.067

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  4 in total

Review 1.  Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies.

Authors:  Yanbo Zhang; Xiong-Fei Pan; Junxiang Chen; Lu Xia; Anlan Cao; Yuge Zhang; Jing Wang; Huiqi Li; Kun Yang; Kunquan Guo; Meian He; An Pan
Journal:  Diabetologia       Date:  2019-09-04       Impact factor: 10.122

Review 2.  Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease.

Authors:  Yumin Gao; Eric Peterson; Neha Pagidipati
Journal:  Clin Cardiol       Date:  2019-08-26       Impact factor: 2.882

3.  Increased Levels of Serum Glycosylated Hemoglobin are Associated with Depressive Symptoms in a Population with Cancer (≥49 Years): An Antidepressant-Stratified Analysis.

Authors:  Ying Huang; Yilin Xu; Anwen Liu
Journal:  Clin Interv Aging       Date:  2021-02-02       Impact factor: 4.458

4.  A Prediction Model Based on Noninvasive Indicators to Predict the 8-Year Incidence of Type 2 Diabetes in Patients with Nonalcoholic Fatty Liver Disease: A Population-Based Retrospective Cohort Study.

Authors:  Xintian Cai; Qing Zhu; Yuanyuan Cao; Shasha Liu; Mengru Wang; Ting Wu; Jing Hong; Ayguzal Ahmat; Xiayire Aierken; Nanfang Li
Journal:  Biomed Res Int       Date:  2021-05-14       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.